论文信息 - Newly approved cancer drugs in China — innovation and clinical benefit - 字舞流文

Newly approved cancer drugs in China — innovation and clinical benefit

A. Wagner | X. Guan | Yichen Zhang

[1] Ziyue Xu,et al. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020 , 2022, JAMA network open.

[2] A. Haslam,et al. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action , 2021, JAMA network open.

[3] Yu Qin,et al. Trends in oncology drug innovation in China , 2020, Nature reviews. Drug discovery.

[4] A. Kesselheim,et al. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study , 2020, BMJ.

[5] H. Naci,et al. Why the drug development pipeline is not delivering better medicines , 2015, BMJ : British Medical Journal.

[6] A. Lo,et al. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. , 2014, JAMA otolaryngology-- head & neck surgery.

[7] A. Kesselheim,et al. Defining “Innovativeness” in Drug Development: A Systematic Review , 2013, Clinical pharmacology and therapeutics.

[8] A. Kesselheim,et al. The most transformative drugs of the past 25 years: a survey of physicians , 2013, Nature Reviews Drug Discovery.

[9] J. Aronson,et al. Defining rewardable innovation in drug therapy , 2012, Nature Reviews Drug Discovery.

[10] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.